Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer.
Saved in:
| Title: | Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer. |
|---|---|
| Authors: | Li C; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA., Madan RA; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA., Lee MJ; Developmental Therapeutics Branch, National Cancer Institute, Bethesda, Maryland, USA., Lee S; Developmental Therapeutics Branch, National Cancer Institute, Bethesda, Maryland, USA., Sato N; Developmental Therapeutics Branch, National Cancer Institute, Bethesda, Maryland, USA., Rastogi S; Developmental Therapeutics Branch, National Cancer Institute, Bethesda, Maryland, USA., Shrestha R; Developmental Therapeutics Branch, National Cancer Institute, Bethesda, Maryland, USA., Aragon-Ching JB; Inova Schar Cancer Institute, Fairfax, Virginia, USA., Goswami M; Center for Immuno-Oncology, National Cancer Institute, Bethesda, Maryland, USA., Donahue RN; Center for Immuno-Oncology, National Cancer Institute, Bethesda, Maryland, USA., Cordes LM; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA., Baj A; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA., Seo CCY; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA., Terrigino NT; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA., Bright JR; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA., Hennigan ST; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA., King IM; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA., Trostel SY; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA., Fenimore JM; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA., Liu Y; Genetics Branch, National Cancer Institute, Bethesda, Maryland, USA., Calzone KA; Genetics Branch, National Cancer Institute, Bethesda, Maryland, USA., Schlom J; Center for Immuno-Oncology, National Cancer Institute, Bethesda, Maryland, USA., Gulley JL; Center for Immuno-Oncology, National Cancer Institute, Bethesda, Maryland, USA., Dahut WL; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA., Figg WD; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA., Sowalsky AG; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA., Lee JM; Women's Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA., Karzai F; Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA fatima.karzai@nih.gov. |
| Source: | Journal for immunotherapy of cancer [J Immunother Cancer] 2026 Mar 25; Vol. 14 (3). Date of Electronic Publication: 2026 Mar 25. |
| Publication Type: | Journal Article; Clinical Trial, Phase II |
| Journal Info: | Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
